secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K/A
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001193125-25-228331
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

enGene Holdings appoints Astley-Sparke and Heffernan to board committees
------------------------------------------------------------------------

- Philip Astley-Sparke appointed to Audit Committee and Nominating & Corporate Governance Committee.
- Michael Heffernan appointed to Audit Committee and Compensation Committee.
- Committee assignments effective October 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525228331/0001193125-25-228331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525228331/engn-20250707.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-228331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer